MEN-10755. Menarini.
Menarini is developing the anthracycline aminodisaccharide MEN-10755 for the potential treatment of solid tumors. Six phase II trials began in 2000 to verify the therapeutic activity of the drug in a variety of tumors, including sarcoma and those of the ovary, breast, prostate and lung.
Jones
Kellie
K
University of Texas MD Anderson Cancer Center, Department of Pharmacy, 1515 Holcombe Boulevard, Houston, TX 77030, USA. kljones@mdanderson.org
D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D004187:Disaccharides / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D015507:Drugs, Investigational / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D013678:Technology, Pharmaceutical / Q000379:methods; D059005:Topoisomerase II Inhibitors
D004187:Disaccharides; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D059005:Topoisomerase II Inhibitors; D004317:Doxorubicin; D004250:DNA Topoisomerases, Type II; C107602:sabarubicin